This invention relates generally to Transcutaneous Electrical Nerve Stimulation (TENS) devices that deliver electrical currents across the intact skin of a user via electrodes to provide symptomatic relief of pain. More specifically, this invention discloses apparatus and methods for controlling the operation of a TENS device without requiring mechanical actuators (e.g., physical push-buttons).
Transcutaneous electrical nerve stimulation (TENS) is the delivery of electricity (i.e., electrical stimulation) across the intact surface of a user's skin in order to activate sensory nerve fibers. The most common application of TENS therapy is to provide analgesia, such as for alleviation of chronic pain. Other applications of TENS therapy include, but are not limited to, reducing the symptoms of restless leg syndrome, decreasing nocturnal muscle cramps, and providing relief from generalized pruritus.
In conventional TENS, electrodes are placed on the skin within, adjacent to, or proximal to, the area of pain. In fixed-site high-frequency TENS, the electrodes are placed in an anatomically and physiologically optimal area (e.g., the upper calf of the user) that results in widespread analgesia. An electrical circuit generates stimulation pulses with specified characteristics. One or more pairs of electrodes, placed on the patient's skin, transduce the electrical pulses and thereby stimulate underlying nerves to relieve pain.
A conceptual model for how sensory nerve stimulation leads to pain relief was proposed by Melzack and Wall in 1965. Their theory proposes that the activation of sensory nerves (Aβ fibers) closes a “pain gate” in the spinal cord that inhibits the transmission of pain signals carried by nociceptive afferents (C and Aδ fibers) to the brain. In the past 20 years, anatomic pathways and molecular mechanisms that may underlie the pain gate have been identified. Sensory nerve stimulation (e.g., via TENS) activates the descending pain inhibition system, primarily the periaqueductal gray (PAG) and rostroventral medial medulla (RVM) located in the midbrain and medulla sections of the brainstem, respectively. The PAG has neural projections to the RVM, which in turn has diffuse bilateral projections into the spinal cord dorsal horn that inhibit ascending pain signal transmission.
TENS is typically delivered in short discrete pulses, with each pulse typically being several hundred microseconds in duration, at frequencies of between about 10 Hz and about 150 Hz, through hydrogel electrodes placed on the user's body. TENS is characterized by a number of electrical parameters including the amplitude and shape of the stimulation pulse (which combine to establish the pulse charge), the frequency and pattern of the pulses, the duration of a therapy session, and the interval between therapy sessions. All of these parameters are correlated to the therapeutic dose. For example, higher amplitude and longer pulses (i.e., larger pulse charges) increase the dose, whereas shorter therapy sessions decrease the dose. Clinical studies suggest that pulse charge and therapy session duration have the greatest impact on therapeutic dose.
User control over a TENS device is typically provided with mechanical actuators directly wired to the electronic circuits regulating electrical stimulation. These actuators are usually push-buttons and/or dials. To achieve maximum pain relief (i.e., hypoalgesia), TENS needs to be delivered at an adequate stimulation intensity. Intensities below the threshold of sensation are not clinically effective. The optimal therapeutic intensity is often described as one that is “strong yet comfortable”. Most TENS devices rely on the user to set the stimulation intensity, usually through a manual intensity control comprising an analog intensity knob or digital intensity control push-buttons.
Pain relief from TENS stimulation usually begins within 15 minutes of the stimulation onset and may last up to an hour following the completion of the stimulation period (which is also known as a “therapy session”). Each therapy session typically runs for 30-60 minutes. To maintain maximum pain relief (i.e., hypoalgesia), TENS therapy sessions typically need to be initiated at regular intervals.
Recently, wearable TENS devices have been introduced (e.g., the SENSUS® and Quell® TENS devices from NeuroMetrix, Inc. of Waltham, Mass.) where the device is intended to be worn on the body of a user for prolonged periods of time, including while sleeping. In order to be comfortable and wearable under clothing, such devices must have a low profile. It is therefore advantageous that these devices have no mechanical actuators (e.g., push-buttons). Furthermore, it is difficult to locate and actuate a push-button under clothing unless the push-button is large. However, a large push-button increases the size, thickness, and manufacturing complexity of the device, thereby decreasing the wearability of the device. Moreover, push-buttons and other mechanical actuators are prone to accidental activation such as when the user is sleeping.
A smartphone “App” can be used to control operation of a TENS device wirelessly through a Bluetooth or similar wireless communication protocol. This requires the TENS device to maintain an active communication link with the smartphone App in order to respond to control commands from the smartphone App and to exchange information between the TENS device and the App. Maintaining a continuous active communication link between the TENS device and the smartphone App can be expensive in terms of battery power consumption, leading to the need for frequent recharges and user inconvenience.
To improve wearability and comfort, portable TENS devices must have a small total volume and low profile. Volume requirements put an upper limit on the physical size of a rechargeable battery contained within the TENS device. The capacity of the battery powering the TENS device, which is typically somewhat proportional to the size of the battery, is thus limited in such wearable TENS devices. To extend battery life, it is necessary to transition the TENS device from an active to a power-saving state when the TENS device is not in use, and to transition the TENS device back to an active state when the TENS device is to be used, all in an intuitive and reliable manner.
The present invention comprises the provision and use of a novel TENS device without requiring the use of mechanical actuators (e.g., push-buttons, switches, dials, etc.). The states (active and power-saving) and the operation of the TENS device are controlled through intentional gestures and other means. In one preferred form of the invention, a three-axis accelerometer is incorporated into the TENS device and measures the motion and orientation of the TENS device caused by user hand gestures such as taps, flicks, and shakes, and alters the device states (active and power-saving) and operations accordingly.
Other control means may be provided for controlling the state and operation of the TENS device via wireless connections, including RFID (radio-frequency identification tag) and other similar near-field communication devices (including an App running on a Bluetooth-enabled smartphone).
Additional device control schemes include the automatic initiation of therapy upon device placement on the skin of the user, and transitions into and out of a power-saving mode based on general movements sensed by the TENS device.
In one preferred form of the invention, there is provided apparatus for transcutaneous electrical nerve stimulation in a user, said apparatus comprising:
a stimulator for electrically stimulating at least one nerve;
a stimulator housing;
a monitor for monitoring transient motion of said stimulator housing;
an analyzer for analyzing transient motion monitored by said monitor for determining whether transient motion of said stimulator housing has occurred; and
a controller for automatically transitioning at least one of said stimulator, said monitor, and said analyzer between a standby mode and a power save mode;
wherein said power save mode supports a subset of the functionality of said stimulator and said monitor which is available in said standby mode so as to conserve battery power in said power save mode.
In another preferred form of the invention, there is provided apparatus for transcutaneous electrical nerve stimulation in a user, said apparatus comprising:
a stimulator for electrically stimulating at least one nerve;
a pair of electrodes connectable to said stimulator for electrical stimulation of said at least one nerve;
an on-skin detector electrically connected to said stimulator for monitoring impedance between said pair of electrodes and the body of a user in order to determine the on-skin status of said pair of electrodes; and
a controller for automatically transitioning said stimulator between a standby mode and an active mode;
wherein said stimulator delivers electrical stimulation to the user in said active mode.
In another preferred form of the invention, there is provided apparatus for transcutaneous electrical nerve stimulation in a user, said apparatus comprising:
a stimulator for electrically stimulating at least one nerve;
a stimulator housing;
a monitor for monitoring the transient motion of said stimulator housing;
a remote controller for indicating the proximity of a hand of a user to said monitor;
an analyzer for analyzing transient motion monitored by said monitor for determining whether transient motion of said stimulator housing is caused by an intentional hand gesture by a user; and
a controller for automatically modifying operation of said stimulator in response to said intentional hand gesture;
wherein said proximity indicated by said remote controller modifies operation of said analyzer.
In another preferred form of the invention, there is provided a method for controlling transcutaneous electrical nerve stimulation without mechanical actuators or buttons, said method comprising the steps of:
providing apparatus for transcutaneous electrical nerve stimulation in a user, said apparatus comprising:
determining presence of transient motion based on measurements from said monitor; and
transitioning at least one of said stimulator, said monitor, and said analyzer between said standby mode and said power save mode.
In another preferred form of the invention, there is provided a method for controlling transcutaneous electrical nerve stimulation without mechanical actuators or buttons, said method comprising the steps of:
providing apparatus for transcutaneous electrical nerve stimulation in a user, said apparatus comprising:
determining on-skin status of said pair of electrodes; and
transitioning said stimulator between said standby mode and said active mode.
In another preferred form of the invention, there is provided a method for controlling transcutaneous electrical nerve stimulation without mechanical actuators or buttons, said method comprising the steps of:
providing apparatus for transcutaneous electrical nerve stimulation in a user, said apparatus comprising:
modifying operation of said analyzer based on proximity information from said remote controller;
determining the presence of an intentional hand gesture by the user based on measurements from said monitor; and
controlling operation of said stimulator based on said intentional hand gesture.
In another preferred form of the invention, there is provided apparatus for transcutaneous electrical nerve stimulation in a user, said apparatus comprising:
a stimulator for electrically stimulating at least one nerve;
a stimulator housing;
a monitor for monitoring the transient motion of said stimulator housing;
an analyzer for analyzing transient motion monitored by said monitor for determining whether transient motion of said stimulator housing is caused by an intentional gesture by a user; and
a controller for automatically modifying operation of said stimulator in response to said intentional gesture.
In another preferred form of the invention, there is provided a method for controlling transcutaneous electrical nerve stimulation without mechanical actuators or buttons, said method comprising the steps of:
providing apparatus for transcutaneous electrical nerve stimulation in a user, said apparatus comprising:
determining the presence of an intentional hand gesture by the user based on measurements from said monitor; and
controlling operation of said stimulator based on said intentional gesture.
These and other objects and features of the present invention will be more fully disclosed or rendered obvious by the following detailed description of the preferred embodiments of the invention, which is to be considered together with the accompanying drawings wherein like numbers refer to like parts, and further wherein:
The present invention comprises the provision and use of a novel TENS device with a stimulator designed to be placed on a user's upper calf (or other anatomical location) and a pre-configured electrode array designed to provide electrical stimulation to at least one nerve disposed in the user's upper calf (or other anatomical location). A key feature of the present invention is that the novel TENS device contains no mechanical actuators (e.g., push-buttons, switches, dials, etc.) for controlling operation of the TENS device.
More particularly, and looking now at
Looking next at
In one preferred form of the invention, stimulator housing 111 also houses a battery (not shown) for powering the TENS stimulation circuitry and other circuitry, and other ancillary elements, such as a wireless link module 185 (
In another form of the invention, TENS device 100 may comprise more than one stimulator housing 111, e.g., to better conform to the body and/or to improve user comfort by distributing circuitry and battery components more evenly.
And in still another form of the invention, a flexible circuit board is used to distribute the TENS stimulation circuitry and other circuitry more evenly around the leg of the user and thereby reduce the thickness of the device.
Still looking at
In one preferred form of the invention, TENS device 100 is configured to be worn on the user's upper calf 140 as is shown in
Electrical current (i.e., for therapeutic electrical stimulation to the tissue) is provided to the electrode pairs 304, 306 and 302, 308 by connectors 310, 312 (
In one preferred form of the present invention, the skin-contacting conductive material of electrodes 302, 304, 306, 308 is a hydrogel material which is “built into” electrodes 302, 304, 306, 308. The function of the hydrogel material on the electrodes is to serve as an interface between the electrodes 302, 304, 306, 308 and the skin of the user (i.e., within, or adjacent to, or proximal to, the portion of the user's body in which the sensory nerves which are to be stimulated reside). Other types of electrodes such as dry electrodes and non-contact stimulation electrodes have also been contemplated and are considered to be within the scope of the present invention.
In prior U.S. patent application Ser. No. 13/678,221, filed Nov. 15, 2012 by Neurometrix, Inc. and Shai N. Gozani et al. for APPARATUS AND METHOD FOR RELIEVING PAIN USING TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, issued as U.S. Pat. No. 8,948,876 on Feb. 3, 2015, and which patent is hereby incorporated herein by reference, apparatus and methods are disclosed for allowing a user to personalize the TENS therapy stimulation intensity according to the electrotactile perception threshold of the user at the time of the setup of the TENS device. The aforementioned U.S. Pat. No. 8,948,876 also discloses apparatus and methods to automatically restart additional therapy sessions after an initial manual start by the user.
In prior U.S. patent application Ser. No. 14/230,648, filed Mar. 31, 2014 by NeuroMetrix, Inc. and Shai Gozani et al. for DETECTING CUTANEOUS ELECTRODE PEELING USING ELECTRODE-SKIN IMPEDANCE, issued as U.S. Pat. No. 9,474,898 on Oct. 25, 2016, and which patent is hereby incorporated herein by reference, apparatus and methods are disclosed which allow for the safe delivery of TENS therapies at night when the user is asleep. These methods and apparatus allow the TENS device to be worn by a user for an extended period of time, including 24 hours a day.
In order to deliver consistently comfortable and effective pain relief to a user throughout both the day and the night, it may not be appropriate to deliver a fixed TENS stimulation level, since the effect of circadian or other time-varying rhythms can mitigate the effectiveness of TENS stimulation. Parameters impacting TENS stimulation effectiveness include, but are not limited to, stimulation pulse amplitude 493 (
For users to gain the full benefit of pain relief throughout both the day and the night from a TENS device, the TENS device should have a low profile for wearability, an easy and intuitive control for usability, and a long-lasting battery life for portability.
Mechanical actuators such as push-buttons and dials increase the physical dimensions of a TENS device. Furthermore, it is difficult to locate and actuate a push-button or dial under clothing unless the push-button or dial is large. However, a large push-button or dial increases the size, thickness, and manufacturing complexity of the device, thereby decreasing its wearability. Moreover, push-buttons and other mechanical actuators are prone to accidental activation such as when the user is sleeping. Therefore, the present invention allows the elimination of mechanical actuators (e.g., push-buttons, dials, etc.) from the TENS device.
Intuitive and easy control enhances the usability of the TENS device. User gestures such as flick, shake, and tap are intuitive ways for a user to interact with their TENS device. The present invention discloses apparatus and methods for processing signals from an on-board accelerometer in order to accurately interpret user gestures.
Extended battery life between charges is a desirable feature for any portable device, especially a TENS device needed for pain relief throughout both the day and the night. However, small total volume and low profile requirements limit the size of rechargeable battery embedded inside a TENS device, and battery capacity is generally related to battery size. Therefore, the capacity of the battery powering the TENS device is thus limited. The present invention discloses apparatus and methods for efficiently managing the power consumption of the TENS device by transitioning the TENS device from an active state to a power-saving state when the TENS device is not in use, and then transitioning the TENS device back to an active state when the TENS device is to be used, all in an intuitive and reliable manner.
In one preferred form of the invention, TENS device 100 operates in one of three modes (see
(i) an Active mode 176 where TENS device 100 delivers electrical stimulation to the user and maintains an active communication link with remote controller 180;
(ii) a Standby mode 174 where TENS device 100 is ready to start delivering electrical stimulation and maintains an active communication link with remote controller 180; and
(iii) a PowerSave mode 172 where TENS device 100 is ready to transition to Standby mode with specific event triggers. Note that it is generally advantageous for TENS device 100 to be in its PowerSave mode whenever possible inasmuch as the Standby mode consumes up to ten times more power than the PowerSave mode.
In PowerSave mode 172, TENS device 100 will turn off all circuitry except for the circuitry of accelerometer 132, which is left active in order to detect gross movement of TENS device 100. The accelerometer circuitry, running a simple motion detection algorithm (e.g., a threshold detector wherein movement is detected when any acceleration signal with an absolute value greater than a threshold value is measured) requires little power for movement detection. Once movement is detected by accelerometer 132, the circuitry of accelerometer 132 sends a signal to the processor 515 (
In Standby mode, TENS device 100 activates wireless link module 185, on-skin detector 265, and accelerometer 132. When no “qualified event” occurs within a pre-determined time window, processor 515 returns TENS device 100 to its PowerSave mode. In one form of the invention, the pre-determined time window is 5 minutes. “Qualified events” include communications from/to remote controller 180, specific movement patterns detected by accelerometer 132 (e.g., a tap, a shake, a flick, etc.), and the detection of an on-skin condition. Determination of qualified events is discussed in detail later below. In a preferred form of the invention, processor 515 changes TENS device 100 from its Standby mode to its Active mode by initiating a therapy session after a pre-determined time delay from when the on-skin condition is detected (i.e., the on-skin condition flag transitions from false to true). By way of example but not limitation, the pre-determined time delay may be 20 seconds. In another form of the invention, TENS device 100 remains in its Standby mode as long as an on-skin condition is detected (i.e., the on-skin condition flag is true) and an additional command is needed to initiate a therapy session.
In Active mode, TENS device 100 provides electrical stimulation to the user for a pre-determined period of time and then returns to Standby mode. In a preferred form of the invention, processor 515 starts a timer when TENS device 100 enters its Standby mode from its Active mode, and then automatically initiates the next therapy session at a set time interval if TENS device 100 is still on the skin of the user (i.e., if the on-skin status of TENS device 100 remains true).
If the on-skin condition of TENS device 100 turns false in Active mode, processor 515 will automatically stop electrical stimulation and return the TENS device to Standby mode.
It should be appreciated that processor 515 may comprise a general purpose microprocessor (CPU) of the sort well known in the art together with appropriate programming to provide the functionality disclosed herein, including, among other things, providing the gesture recognition functionality (see below), the tap and flick (pulse) detector functionality (see below), the pulse screener functionality (see below), the pulse analyzer functionality (see below), and the transient motion detector functionality (see below).
In one preferred form of the invention, TENS device 100 comprises on-skin detector 265 (
More particularly, stimulator 110 will automatically initiate an electrical stimulation therapy session after a pre-determined period of delay (e.g., 20 seconds) after the TENS device is secured to the user. In a preferred form of the invention, on-skin detector 265 (
In the preferred form of the invention, and looking now at
On-skin detector 265 is preferably employed in the following way.
If on-skin detector 265 indicates that electrode array 300 of TENS device 100 has become partially or fully detached from the skin of the user, TENS device 100 stops applying TENS therapy to the user and processor 515 of TENS device 100 will transition operation of TENS device 100 from Active mode to Standby mode.
When TENS device 100 is in its Standby mode and on-skin detector 265 determines that the TENS device is not on-skin, the TENS device cannot begin TENS therapy. Therefore, processor 515 disables the user gesture detection for gestures related to TENS therapy such as those gestures for starting and stopping a therapy and those gestures for adjusting therapy intensity (see below). Among the advantages of detecting a smaller set of gestures by processor 515 are: (1) the detection accuracy of fewer candidate gestures will be improved; and (2) the circuitry of accelerometer 132 can be operated at a lower power consumption mode to conserve battery. It is well known in the field of pattern classification that using the same feature sets (from the accelerometer signals) will lead to more accurate classification results (i.e., the features associated with a given signal belong to a target user gesture) if the classification candidate count is reduced. In one preferred form of the invention, the candidate gestures may be reduced to two candidates when TENS device 100 is not on the skin: no gesture at all or any interaction (i.e., gesture) with the TENS device. In this case, accelerometer signals can be sampled at a much lower sampling frequency and a much simpler classification algorithm can be run on the circuitry of accelerometer 132 to detect any gross movement. Both lower sampling frequency and simpler algorithms can lead to lower power consumption by the circuitry of accelerometer 132, and thus provide a longer battery life.
Gesture identification and classification apparatus and methods are described in greater detail below.
In one preferred form of the invention, a MEMS-based tri-axial accelerometer 132 is mechanically coupled to housing 111 of TENS device 100. The output of accelerometer 132 is electrically coupled with a microcontroller running motion and gesture algorithms (i.e., processor 515).
The gesture algorithms running on processor 515 reliably identify hand gestures (i.e., hand interaction with housing 111 of the TENS device). These hand gestures include a tap to the housing of the TENS device, a double tap to the TENS device (two consecutive taps within a specified time window 630,
In one preferred form of the invention, TENS device 100 sets the sampling rate of accelerometer 132 at a rate of 400 Hertz when the TENS device is in its Active mode or its Standby mode and disposed the skin of the user (i.e., its on-skin condition is true, so the TENS device is considered to be on-skin), although a different sampling rate can be utilized. Accelerometer 132 is set to sample at a lower rate (e.g., 100 Hertz) when the TENS device is in Standby mode and not on the skin of the user (i.e., its on-skin condition is false, so the TENS device is considered to be off-skin). The determination of the on-skin or off-skin status of TENS device 100 is accomplished by On-Skin Detector 265 and is discussed in greater detail below. When TENS device 100 is in PowerSave mode, the sampling rate of accelerometer 132 is set at an even lower rate (e.g., 50 Hertz) to further reduce power consumption.
In one preferred form of the invention, accelerometer 132 is sampled at 50 Hertz from all three axes (i.e., the X, Y, and Z directions). A segment of sampled data is shown in
where Aj(t) is the accelerometer sample value from the j-axis at the time instance t. A simple threshold detector is sufficient to detect device motion:
S(t)>MTh
where MTh is a fixed threshold 606. In another form of the invention, the summation of the absolute values of the differences is replaced by the square of the differences. In yet another form of the invention, only data from one axis of the accelerometer is considered. In yet another form of the invention, the threshold 606 is set to be an average of previous samples that have not caused a detected motion event.
Any device motion detected will cause processor 515 of TENS device 100 to transition the mode of the TENS device from PowerSave to Standby. If the TENS device is in Standby mode but not on-skin, the TENS device will return to its PowerSave mode if no further interaction from the user is detected before a countdown timer expires. Interaction from the user may include a command from a connected remote controller 180 or a recognized gesture to start therapy. In one form of the invention, the countdown timer is set to five minutes. If the TENS device is already in Standby mode, a detected device motion will reset the countdown timer to delay the transition from Standby mode to PowerSave mode.
In one preferred form of the invention, control of the operation of TENS device 100 is effected using intentional gestures such as those shown in the table below. The tap gesture is a rapid impact of housing 111 of the TENS device. The flick gesture is a short (small distance) rapid movement of the device up or down. Note that the various gestures are context-sensitive, e.g., a tap in the Standby mode may effect a different change in operation than a tap in the Active mode.
The above context-based gesture control of the operation of the TENS device has the advantage that it is intuitive and easy to learn. Most actions are initiated by a simple tap, and the intensity of stimulation is controlled by a flick wherein the direction (up or down) is associated with the change in intensity (i.e., an up flick is associated with an increase in stimulation intensity and a down flick is associated with a decrease in stimulation intensity). For example, when the TENS device is in Standby mode but not on a user's skin, a tap is interpreted as a battery check command, because therapy or calibration cannot be performed in that condition. When the TENS device is in Standby mode and on-skin, a double tap will cause the device to enter a calibration process. During the calibration process, electrical stimulation will ramp up automatically, and a tap becomes an indication of the user's perception of the stimulation sensation, causing the calibration ramp to stop. When the calibration process is completed, the TENS device returns to Standby mode. When the TENS device is in Standby mode and on-skin, a tap will start therapy stimulation (i.e., the TENS device will enter Active mode). When the TENS device is on the user's skin and the device is in Active mode (i.e., electrical stimulation is occurring), the same tap gesture will stop therapy stimulation and return the device to Standby mode.
In another form of the invention, a gyroscope 133 is mechanically coupled with housing 111 of the TENS device. The lower limb movement patterns can be monitored using gyroscope 133 and “decoded” as control inputs to the TENS device. By way of example but not limitation, a user wearing the TENS device on their lower leg, sitting in a chair and with their feet resting on the floor, can maneuver leg sway in a lateral-medial direction (i.e., left and right) easily and discreetly. Gyroscope 133 can detect the pattern and the number of leg sways occurring within a specific time window (e.g., one second) and use this pattern as a TENS control input. For example, a single leg sway detected by gyroscope 133 can be interpreted as equivalent to a single tap detected by accelerometer 132. Depending upon the operational mode of the TENS device (i.e., PowerSave mode, Standby mode and Active mode), the single leg sway movement can be interpreted differently: the leg sway can cause the stimulation to start if the TENS device is in Standby mode and On-Skin; and the leg sway can cause the stimulation to stop if the TENS device is in Active mode delivering electrical stimulation. A single cycle of back and forth leg sway within a given time period (e.g., one second) can, similarly, be treated as equivalent to a double tap. Continuous back and forth leg sway can be detected and such detection outcome can be treated as a different control command for the TENS device.
In another form of the invention, a combination of data received from gyroscope 133 and accelerometer 132 is used to detect a combination of gesture and leg movements for button-free control of the operation of TENS device 100.
In one preferred form of the invention, accelerometer data sampled at 400 Hertz are analyzed to detect certain waveform morphology that corresponds to taps or flicks (collectively, such taps or flicks are referred to herein as pulses). Two taps separated by a time window 630 (
The morphology of waveforms associated with a tap or a flick is very similar. A detection algorithm (i.e., a Pulse Detector) can be used to detect both taps and flicks because the accelerometer signals for both taps and flicks share very similar waveform structures. Expanded views of accelerometer signals associated with tap events are shown in
In one preferred form of the invention, accelerometer data from the Z-axis are used for tap gesture detection, inasmuch as a user is more likely to tap the TENS device in the Z-axis direction (i.e., perpendicular to the skin) when the device is on-skin (i.e., placed on the upper calf as shown in
Pulse Screener
In one preferred form of the invention, high-pass filtered accelerometer data, with static gravity removed, are screened by a pulse screener to flag candidate waveform segments. Any waveform from a specified axis whose absolute value exceeds a threshold, then falls back below that threshold within a pre-determined time window, triggers a flag to indicate that waveform segment as a potential pulse.
Pulse Analyzer
In a preferred form of the present invention, 3-axis accelerometer 132 outputs its raw acceleration measurement data at a rate of 400 Hz for each axial direction (i.e., accelerometer 132 reports 400 acceleration measurements per second for the X-axis direction, 400 acceleration measurements per second for the Y-axis direction, and 400 acceleration measurements per second for the Z-axis direction, for a total of 1200 measurements per second). In a preferred form of the invention, only the acceleration data from the Z-axis, Az(t), are analyzed for the detection of acceleration “pulse” events, i.e., intentional gestures (e.g., taps, slaps, and flicks, etc.) on the TENS device 100 by the user (the Z-axis is sometimes hereinafter referred to as the “primary axis”). In another form of the invention, acceleration data from each of the three axes are analyzed independently for detection of acceleration “pulse” events. In yet another form of the invention, the acceleration data from all three directions are combined into instantaneous acceleration A(t), defined as
A(t)=√{square root over (Ax(t)2+Ay(t)2+Az(t)2)}
and this instantaneous acceleration signal is analyzed for detection of acceleration “pulse” events.
The defining characteristic of an acceleration pulse event (sometimes referred to herein as simply a “pulse”), generated by a tap or similar user gesture, is that acceleration exceeds a threshold (i.e., a positive or negative acceleration threshold), and returns below that threshold within a specified time period (i.e., a time duration threshold). The acceleration data are first high-pass filtered to remove the constant effect of gravity. In a preferred form of the invention, the high-pass filter cut-off frequency is set at 2 Hz in order to remove the effect of gravity while still permitting a range of other uses for the accelerometer data.
For true tap events (i.e., those reflective of an intentional user gesture), the pulse is typically largest and more stereotyped along the primary axis (i.e., along the Z-axis). As a result, in a preferred form of the invention, pulse detection is enabled on only the Z-axis in order to improve detection of true pulse events and limit “false” pulse events (i.e., those not reflective of an intentional user gesture). In another form of the invention, pulse detection is carried out on all three axes. Corresponding threshold values for each axis may be different, depending upon the configuration of TENS device 100. In one form of the invention, a pulse detection outcome is considered to be positive (i.e., a pulse is considered to have been detected) only if the pulse detection in all axis directions under consideration is positive. In another form of the invention, the pulse detection outcome is considered to be positive if the pulse detection in any axis direction under consideration is positive. In yet another form of the invention, the pulse detection outcome is considered to be positive if the pulse detection outcome is positive for a majority of the axes under consideration.
Depending upon the manner in which the user interacts with the TENS device, either the positive or negative peak of the pulse (i.e., the acceleration trace waveform) may be larger and cross detection threshold 702 or 712. In a preferred form of the invention, crossing either positive threshold 712 or negative threshold 702, and returning within the specified time duration period, is considered to constitute the detection of a pulse event. In other words, acceleration peaks lying between threshold 712 and threshold 702 do not constitute a pulse event, and threshold 712 and threshold 702 together effectively form a non-pulse band. A pulse event is detected when the acceleration trace waveform 701 goes outside the non-pulse band briefly for a time duration greater than zero but smaller than the specified time duration period. In one preferred form of the invention, both thresholds (i.e., thresholds 702 and 712) may have the same magnitude or absolute value. In another form of the invention, positive threshold 712 is larger than negative threshold 702 (in absolute value), effectively requiring that the pulse waveform have a larger positive peak in order to be recognized as a pulse event. In yet another form of the invention, positive threshold 712 is set to a very large number, exceeding the largest possible measured acceleration value. Setting positive threshold 712 to such a very large number effectively causes pulse detector 515 to ignore the positive pulse peak and requires the pulse waveform to have negative polarity (i.e., a negative peak with an amplitude exceeding threshold 702) in order to constitute a pulse event.
Thus it will be seen that the pulse detector (an algorithm implemented by processor 515) utilizes a pulse detection algorithm that has two main parameters: positive and negative amplitude thresholds (measured in units g, standard gravity acceleration), and a time duration threshold (measured in units msec). In a preferred form of the invention, the amplitude threshold values and the time duration threshold values are fixed values which are derived experimentally, e.g., from a population study. Based on one population study, the parameters are set as follows: positive amplitude threshold: +1 g, negative amplitude threshold: −1 g, and time duration threshold: 15 msec. In another form of the invention, the amplitude threshold values and the time duration threshold value are adapted to the behavior of an individual user. For example, if a stronger pulse waveform always follows a weaker pulse waveform (i.e., the weaker pulse waveform just misses the threshold value 702 and the stronger pulse waveform exceeds the threshold 702), threshold value 702 may be reduced (in absolute value) to allow pulse detector 515 to correctly recognize a weaker tap as a “true” acceleration pulse event (and hence an intentional user gesture). Similar process may be used for adaptation and differentiation of the threshold values in different axes. As discussed above, the same processor 515 can be used to detect a flick pulse, with a lower amplitude threshold (e.g., >0.3 g) and time duration range between 25 ms and 75 ms.
Transient Motion Detector
Processor 515 of TENS device 100 comprises a transient motion detector for detecting transient motion during walking, etc. The defining feature of transient motion is that the high-pass filtered acceleration waveform exceeds some amplitude threshold, and remains above that amplitude threshold, for at least some time duration. More particularly,
The transient motion detection algorithm utilized by the transient motion detector of processor 515 utilizes three main parameters: positive and negative amplitude thresholds (measured in units g), and duration threshold (measured in units msec). In a preferred form of the invention, the duration threshold is converted to an equivalent discrete sample counter value for a discretely sampled waveform. In a preferred form of the invention, positive and negative amplitude threshold values, and the counter threshold value, are fixed values which are derived experimentally, e.g., from a population study. Based on one population study, the parameters are preferably set as follows: positive amplitude threshold: +0.0625 g, negative amplitude threshold: −0.0625 g, and duration threshold: 15 msec (which corresponds to a counter threshold equal to 6 for waveforms sampled at 400 Hz). In another form of the invention, positive and negative amplitude threshold values, and the counter threshold value, are adapted to an individual user's behavior.
Integration of Transient Motion Detector and Pulse Analyzer: Pulse Detector
When a user intentionally taps TENS device 100, an acceleration pulse event (or “pulse event”) is created which is readily identified by the aforementioned pulse detection algorithm utilized by the pulse detector of processor 515 (i.e., the pulse detector is designed to have high sensitivity so as to ensure reliable detection of the acceleration pulse event). However, pulse events must correspond to actual tap events initiated by the user in order for the gesture control to be of practical value, i.e., the overall system must have high specificity. Inasmuch as transient motion such as walking can lead to “false” pulse events, these “false” pulse events must be identified and rejected without reducing the sensitivity to “true” pulse events (i.e., those reflecting intentional user gestures). Because the underlying cause of “false” pulse events is transient body motion, the present invention detects transient motion due to walking and other normal body movements, and rejects pulse events in close temporal proximity to transient motion. In other words, the pulse detection algorithm of the pulse detector of processor 515 must be sensitive so that it does not miss the detection of “true” pulse events caused by intentional user gestures (e.g., taps by the user on TENS device 100), but the TENS device must also be capable of discerning “false” pulse events caused by walking and other normal body movements and rejecting such “false” pulse events as being unrelated to intentional user gestures.
The temporal proximity of transient motion and acceleration pulse events provides a reliable means for discriminating between “true” acceleration pulse events corresponding to actual user gestures (e.g., taps on TENS device 100), and “false” acceleration pulse events caused by transient motion due to walking and other normal body movement. An important aspect of the present invention lies in this recognition and the determination of such temporal proximity.
Pulse events have sharp initial deflections lasting 10-20 msec, followed by decaying oscillations lasting 50-100 msec. Thus, even “true” pulse events (i.e., those reflective of an intentional user gesture) generate transient motion events immediately after the “true” pulse event. Therefore, in a preferred form of the invention, transient motion events immediately following pulse events are ignored for purposes of discriminating between “true” pulse events and “false” pulse events. However, transient motion events temporally separated from pulse events are used to discriminate between “true” pulse events and “false” pulse events.
More particularly,
The acceleration data 780 from the primary axis direction (Az(t)) are processed by the pulse detector algorithm of processor 515 (block 782). The current pulse detection result P, and a history of transient motion detection results (summarized by flag M), are analyzed by the processor 515 (block 790). When a pulse is detected (i.e., pulse detect flag P is “true”), if transient motion is absent (i.e., if transient motion flag M is “false”), then processor 515 accepts the pulse event as a “true” pulse event (block 792) which is reflective of an intentional user gesture, otherwise processor 515 rejects the pulse event as a “false” pulse event (block 794).
The temporal proximity of transient motion and acceleration pulse events provides the means for discriminating between “true” acceleration pulse events corresponding to actual user gestures (e.g., taps on TENS device 100), and “false” acceleration pulse events caused by transient motion due to walking and other normal body movement. The duration of the buffers (block 786) sets the degree of temporal proximity required between transient motion events and acceleration pulse events when discriminating between “true” acceleration pulse events and “false” acceleration pulse events.
In a preferred form of the invention, the duration of the buffers (block 786) is determined by an optimization procedure based upon data acquired from users wearing the device.
One key factor in this optimization is the following. By the laws of physics, and specifically the laws of kinematics, linear displacement of an object from one relatively stationary state to another relatively stationary state involves acceleration in one direction (initiation of movement) followed by acceleration in the opposite direction (cessation of movement). Accelerometer data from a pulse, like that shown in
TENS device 100 can also be controlled by a remote controller 180. Examples of such a remote controller include an App running on a Bluetooth-enabled smartphone, a finger ring with a RFID (radio frequency identification) tag, a bracelet with an RFID tag, etc. Operation of TENS device 100 can be controlled directly by commands sent to TENS device 100 via a secure wireless link from remote controller 180 to the TENS device. Remote controller 180 can also serve to supplement other schemes for controlling TENS device 100, or to modify other schemes for controlling TENS device 100, e.g., the aforementioned gesture control. By way of example but not limitation, TENS device 100 can be configured to allow a tap gesture to be detected more readily (i.e., for threshold parameters to be relaxed) if an RFID ring or bracelet is detected near the TENS device.
Radio Frequency Identification (RFID) Tag
Radio Frequency Identification (RFID) uses electromagnetic fields to transmit electronically-stored information remotely to a nearby RFID reader. Two types of RFID tags are generally available: passive and active. Passive RFID tags collect energy from the probing radio waves of a nearby RFID reader and use that energy to transmit signals from the RFID tag to the RFID reader. Active RFID tags have a local power source (e.g., a battery) to transmit stored information for up to several hundreds of meters.
In one preferred form of the invention, a passive RFID tag is embedded in a ring to be worn on a user's finger. An RFID reader is embedded in the TENS device. When the RFID ring (i.e., the remote controller 180) is placed close to the TENS device, the RFID reader and the RFID tag exchange appropriate security information. After the RFID tag is validated to determine that information from this RFID tag (i.e., the ring worn on the user's finger) is intended for the TENS device, information from the RFID ring (i.e., remote controller 180) is transmitted to TENS device 100. This transmission is received by wireless link module 185 of TENS device 100 and is then interpreted by TENS device 100.
In one preferred form of the invention, information from the RFID ring (i.e., remote controller 180) is used to start therapy when the TENS device is in Standby mode 174 and the on-skin status condition is “true”. Similarly, information from the RFID ring is used to stop therapy (i.e., to stop electrical stimulation) when the TENS device is in Active mode 176 (i.e., delivering therapeutic stimulation pulses to the user).
In another preferred form of the invention, the presence of a validated RFID ring modifies the behavior of the Pulse Detector of processor 515 so as to improve the responsiveness of the TENS device to user gestures (see
RFID ring can be used to customize the Pulse Analyzer of processor 515 to individual gesture patterns so as to improve its performance. By way of further example but not limitation, each person has a different preferred pace for a double tap (i.e., the time delay between two taps intended to be a double tap, 630 in
In addition to being used to customize operation of the Pulse Analyzer of processor 515, the RFID ring can also be used to customize other aspects of the TENS device. By way of further example but not limitation, each person has their own preferred TENS therapy profile, including stimulation intensity (stimulation pulse amplitude 493) and stimulation pulse patterns (such as pulse frequency 495, therapy session duration 482, and intervals between consecutive therapy sessions). A TENS device may store multiple therapy profiles, and the profile specific to an individual may be loaded into controller 452 once the information necessary to identify the TENS user is detected from the user's RFID ring. Other customization schemes may include a RFID ring (or other RFID tag) disposed by the bed of the user to automatically transition the TENS device into a nighttime therapy profile (if the user has different stimulation preferences for day and night).
In another form of the invention, a passive RFID tag is embedded in a bracelet worn by the TENS user, or in a key chain carried by the user, etc. RFID tags can also be installed at the entrance(s) to the user's home (or office) to allow the user's TENS therapy profile to toggle between indoor (less active or nighttime) and outdoor (more active or daytime) therapy profiles.
In one preferred form of the invention, TENS device 100 comprises a stimulator 110, a strap 130 with a pocket 112 to hold the housing 111 of the stimulator, and an electrode array 300 that connects to the stimulator (both electrically and mechanically) via connectors 210 and 212. Processor 515 for gesture detection and motion detection is preferably disposed in housing 111 of stimulator 110. Strap 130 allows the TENS device to be placed securely on a user's upper calf 140 in order to provide pain relieving therapy with electrical stimulation pulses.
When TENS device 100 is not placed on the skin, the TENS device (and, more specifically, stimulator housing 111) is typically placed on a stationary surface such as a desktop. If TENS device 100 detects no movement and no active communications from or to a remote controller 180 within a set period of time (e.g., five minutes), the TENS device automatically goes into its PowerSave mode 172. In the PowerSave mode, accelerometer 132 is running at a low power mode for detecting only gross movement based on data sampled at 50 Hertz. The wireless link module 185 will also be turned off to conserve energy in the PowerSave mode.
When a user is ready to use the TENS device, the user will first pick up the TENS device 100. Processor 515 will detect the device motion and transition the TENS device into Standby mode 174. In this Standby mode, the TENS device turns on its wireless link module 185 so that communications with one or more remote controllers 180 can be established or re-established. A single tap on the stimulator housing (acting as User Input 512, see
Through wireless link module 185, a smartphone App (running on remote controller 180) can be used to control operation of the TENS device, e.g., to customize device setup and user preference. Similarly, an RFID tag (such as in the form of an RFID ring) can be used to trigger the TENS device to load an appropriate device setup for the user when the user places the RFID ring close to the TENS device. The RFID tag can be pre-programmed by the user or by the user's caregivers.
When the TENS device is in Standby mode, it will also enable on-skin detection module 265. On-skin detection generally only requires a voltage setting of 20 volts (rather than 100 volts as is required when the TENS device is in Active mode and therapeutic stimulation is required). On-skin detection module 265 sets the on-skin status to “true” once the TENS device is placed on the skin. Before the on-skin status turns true, the accelerometer sampling rate is increased to 100 Hertz (from its PowerSave mode of 50 Hertz) so as to detect gross user gestures (but it does not yet need to be increased to its Active mode 400 Hertz sampling rate inasmuch as valid user gestures are limited at this point). If the on-skin status is not “true” and no further actions (including recognized gesture, active communications from remote controller, and device motion) are detected from the user for five minutes, the TENS device will automatically return to its PowerSave mode.
If the on-skin status is set to true when the TENS device is in its Standby mode, the TENS device will stay in Standby mode 174 until the on-skin status is changed to false or until the TENS device transitions to its Active mode 176. Transition from the Standby mode to the Active mode can be triggered by a command from a remote controller 180 (such as an App running on a smartphone) or by a gesture recognized by processor 515. Under default conditions, Processor 515 sets parameters for recognizing “Start Therapy” gesture (single tap) in a way to ensure high specificity, that is, only the true intended gesture will be recognized to minimize the chance that other activities such as walking are being incorrectly classified as tap. Unintentional start of TENS therapy is undesirable as it may startle the user. However, if a recognized RFID ring is nearby when gesture-like accelerometer data are recorded, processor 515 may “more aggressively” recognize the gesture movement as a single tap as the proximity of the ring is a reliable indication that the user intended to interact with the TENS device by placing his/her hand (with the RFID ring) close to the TENS device.
Instead of a single tap, a user may use a double tap gesture to initiate a calibration process when the TENS device is on-skin. During the calibration process, the stimulation intensity gradually ramps up from an intensity below the electro-tactile sensation threshold. Using a single tap, the user can indicate their sensation threshold to the TENS device when the stimulation intensity rises high enough to cause a sensation of the electrical stimulation. Once the user indicates that the stimulation intensity has risen high enough to cause a sensation of the electrical stimulation (i.e., by providing the user gesture tap), the intensity ramp is stopped.
Assuming that processor 515 is programmed to recognize two single taps with a time delay between 0.3 and 0.6 seconds, if all previously-recognized double taps from this user have a time delay of between 0.3 and 0.4 seconds, processor 515 can update its double tap time delay range to 0.25 to 0.45 seconds to further improve its gesture recognition accuracy.
When TENS device 100 is in its Active mode, it delivers electrical current pulses at an intensity proportional to the user's electro-tactile sensation threshold. The user may wish to adjust the stimulation intensity from time to time. This can be accomplished via a remote controller 180 such as a smartphone App. Pre-programmed RFID tags can also be used to accomplish the same: the user may hold one RFID tag close to the TENS device to increase stimulation intensity and use a different tag for decreasing stimulation intensity.
Gestures like flick up or flick down can also be employed to control the stimulation intensity. Processor 515 is preferably configured to detect a single tap from Z-axis accelerometer data and a flick up or a flick down from Y-axis data. As shown in
On-skin detection module 265 also monitors the interface between electrode array 300 and the user's skin when the TENS device is in its Active mode by calculating the body resistor 208 (or more generally, the electrode-skin interface impedance). When the resistor value increases significantly (e.g., doubling its initial value), the quality of the electrode-skin interface is considered to have degraded significantly. The on-skin detection module 265 then sends a signal to Controller 452 to stop electrical stimulation so as to avoid an uncomfortable stimulation sensation due to a reduced electrode-skin contact area. Stopping electrical stimulation will also transition the TENS device from its Active mode to its Standby mode.
In another preferred form of the invention, instead of waiting for a user gesture (e.g., a single tap) to start a therapy session after TENS device 100 is placed on skin, the TENS device can automatically initiate a therapy session upon the device on-skin status changing to “true”. It is reasonable to assume that if a user places the TENS device on their body, the user is seeking pain relief. This intuitive assumption can be leveraged to automatically initiate therapeutic stimulation. More specifically, and in one specific form of the present invention, upon placement of the TENS device on the upper calf of a user, the device automatically initiates stimulation 20 seconds after the on-skin condition is set to true. Similarly, removal of the TENS device from the body of the user suggests that the user no longer needs pain relief at that time and therefore the TENS device can automatically enter PowerSave mode without waiting for five minutes in Standby mode before entering the PowerSave mode, whereby to further optimize battery life.
It should be understood that many additional changes in the details, materials, steps and arrangements of parts, which have been herein described and illustrated in order to explain the nature of the present invention, may be made by those skilled in the art while still remaining within the principles and scope of the invention.
This patent application is a continuation of pending prior U.S. patent application Ser. No. 16/010,974, filed Jun. 18, 2018 by Neurometrix, Inc. for APPARATUS AND METHOD FOR BUTTON-FREE CONTROL OF A WEARABLE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR USING INTERACTIVE GESTURES AND OTHER MEANS, issued as U.S. Pat. No. 10,940,311, which patent application: (1) is a continuation-in-part of prior U.S. patent application Ser. No. 15/824,351, filed Nov. 28, 2017 by Neurometrix, Inc. and Thomas Ferree et al. for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR WITH USER GESTURE DETECTOR AND ELECTRODE-SKIN CONTACT DETECTOR, WITH TRANSIENT MOTION DETECTOR FOR INCREASING THE ACCURACY OF THE SAME, issued as U.S. Pat. No. 10,130,810, which patent application is a continuation of prior U.S. patent application Ser. No. 14/269,887, filed May 5, 2014 by Neurometrix, Inc. and Thomas Ferree et al. for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR WITH USER GESTURE DETECTOR AND ELECTRODE-SKIN CONTACT DETECTOR, WITH TRANSIENT MOTION DETECTOR FOR INCREASING THE ACCURACY OF THE SAME, issued as U.S. Pat. No. 9,827,420, which in turn: (i) is a continuation-in-part of prior U.S. patent application Ser. No. 14/230,648, filed Mar. 31, 2014 by NeuroMetrix, Inc. and Shai Gozani et al. for DETECTING CUTANEOUS ELECTRODE PEELING USING ELECTRODE-SKIN IMPEDANCE, issued as U.S. Pat. No. 9,474,898, which claims benefit of prior U.S. Provisional Patent Application Ser. No. 61/806,481, filed Mar. 29, 2013 by NeuroMetrix, Inc. and Shai Gozani for DETECTING ELECTRODE PEELING BY RELATIVE CHANGES IN SKIN-ELECTRODE IMPEDANCE; (ii) is a continuation-in-part of prior U.S. patent application Ser. No. 14/253,628, filed Apr. 15, 2014 by Neurometrix, Inc. and Shai Gozani et al. for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR WITH AUTOMATIC DETECTION OF USER SLEEP-WAKE STATE, issued as U.S. Pat. No. 10,279,179, which claims benefit of prior U.S. Provisional Patent Application Ser. No. 61/811,864, filed Apr. 15, 2013 by NeuroMetrix, Inc. and Shai Gozani for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR WITH AUTOMATIC DETECTION OF PATIENT SLEEP-WAKE STATE; (iii) claims benefit of prior U.S. Provisional Patent Application Ser. No. 61/819,159, filed May 3, 2013 by NeuroMetrix, Inc. and Thomas Ferree et al. for TAP DETECTOR WITH HIGH SENSITIVITY AND SPECIFICITY FOR A WEARABLE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR; and (iv) claims benefit of prior U.S. Provisional Patent Application Ser. No. 61/858,150, filed Jul. 25, 2013 by NeuroMetrix, Inc. and Andres Aguirre et al. for MOVEMENT REGULATED TRIP CONDITIONS IN A WEARABLE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR; and (2) claims benefit of prior U.S. Provisional Patent Application Ser. No. 62/524,195, filed Jun. 23, 2017 by Neurometrix, Inc. and Shai N. Gozani et al. for BUTTON-FREE CONTROL OF A WEARABLE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR USING INTERACTIVE GESTURES AND OTHER MEANS. The ten (10) above-identified patent applications are hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1741962 | Theodoropulos | Dec 1929 | A |
4290431 | Herbert et al. | Sep 1981 | A |
D263869 | Sumiyasu | Apr 1982 | S |
4503863 | Katims | Mar 1985 | A |
4605010 | McEwen | Aug 1986 | A |
4738250 | Fulkerson et al. | Apr 1988 | A |
4777711 | Forkner | Oct 1988 | A |
4926863 | Alt | May 1990 | A |
4989605 | Rossen | Feb 1991 | A |
5048523 | Yamasawa et al. | Sep 1991 | A |
5063929 | Bartelt | Nov 1991 | A |
D323561 | Bartelt et al. | Jan 1992 | S |
5121747 | Andrews | Jun 1992 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
D342571 | Givens, Sr. | Dec 1993 | S |
D346029 | Shalvi | Apr 1994 | S |
5350414 | Kolen | Sep 1994 | A |
5429589 | Cartmell et al. | Jul 1995 | A |
5479939 | Ogino | Jan 1996 | A |
5487759 | Bastyr et al. | Jan 1996 | A |
5562718 | Palermo | Oct 1996 | A |
5806522 | Katims | Sep 1998 | A |
D411887 | Agarwala | Jul 1999 | S |
5948000 | Larsen et al. | Sep 1999 | A |
5954758 | Peckham | Sep 1999 | A |
6033370 | Reinbold | Mar 2000 | A |
6099488 | Hung | Aug 2000 | A |
6132387 | Gozani et al. | Oct 2000 | A |
6141587 | Mower | Oct 2000 | A |
6148233 | Owen | Nov 2000 | A |
6161044 | Silverstone | Dec 2000 | A |
D443362 | Storp | Jun 2001 | S |
6266558 | Gozani et al. | Jul 2001 | B1 |
D450313 | Koinuma | Nov 2001 | S |
6430450 | Bach-y-Rita et al. | Aug 2002 | B1 |
D462772 | Lamping et al. | Sep 2002 | S |
6456884 | Kenney | Sep 2002 | B1 |
6611789 | Darley | Aug 2003 | B1 |
6662051 | Eraker et al. | Dec 2003 | B1 |
D484984 | Takizawa et al. | Jan 2004 | S |
D534871 | Larsen | Jan 2007 | S |
D541042 | Andre et al. | Apr 2007 | S |
D547454 | Hsieh | Jul 2007 | S |
D566383 | Harris et al. | Apr 2008 | S |
D584414 | Lash et al. | Jan 2009 | S |
D592200 | Liu | May 2009 | S |
D598556 | Chen | Aug 2009 | S |
D600352 | Cryan | Sep 2009 | S |
D607198 | Andre et al. | Jan 2010 | S |
D609353 | Cryan | Feb 2010 | S |
7668598 | Herregraven et al. | Feb 2010 | B2 |
D611611 | Sachi et al. | Mar 2010 | S |
D615526 | Andre et al. | May 2010 | S |
7720548 | King | May 2010 | B2 |
7725193 | Chu | May 2010 | B1 |
7787946 | Stahmann et al. | Aug 2010 | B2 |
D625016 | Potts et al. | Oct 2010 | S |
D625829 | Arbesman et al. | Oct 2010 | S |
D629115 | Robertson | Dec 2010 | S |
7887493 | Stahmann et al. | Feb 2011 | B2 |
D636881 | Clemens et al. | Apr 2011 | S |
D637988 | Jinkinson | May 2011 | S |
8108049 | King | Jan 2012 | B2 |
8121702 | King | Feb 2012 | B2 |
8131374 | Moore et al. | Mar 2012 | B2 |
D658302 | Nixon | Apr 2012 | S |
8284070 | Chaudhari et al. | Oct 2012 | B2 |
D677792 | Vandiver | Mar 2013 | S |
D680735 | Itabashi et al. | Apr 2013 | S |
8421642 | McIntosh et al. | Apr 2013 | B1 |
D687951 | Della Torre et al. | Aug 2013 | S |
D688707 | Vincent et al. | Aug 2013 | S |
D704848 | Thomas et al. | May 2014 | S |
D705428 | Cheney et al. | May 2014 | S |
D712045 | Thornton | Aug 2014 | S |
D712052 | Thomas et al. | Aug 2014 | S |
D713049 | Shah | Sep 2014 | S |
8825175 | King | Sep 2014 | B2 |
8849407 | Danilov et al. | Sep 2014 | B1 |
D716457 | Brefka et al. | Oct 2014 | S |
8862238 | Rahimi | Oct 2014 | B2 |
D716963 | Yosef et al. | Nov 2014 | S |
8948876 | Gozani et al. | Feb 2015 | B2 |
D732682 | Porat | Jun 2015 | S |
D735873 | Brefka et al. | Aug 2015 | S |
9168375 | Rahimi et al. | Oct 2015 | B2 |
D744661 | Rizzi | Dec 2015 | S |
D745975 | Igaue et al. | Dec 2015 | S |
D750263 | Shigeno et al. | Feb 2016 | S |
D750798 | Yosef et al. | Mar 2016 | S |
9282287 | Marsh | Mar 2016 | B1 |
9282897 | Ross, Jr. et al. | Mar 2016 | B2 |
D754355 | Ganapathy et al. | Apr 2016 | S |
D754973 | Danze et al. | May 2016 | S |
D757292 | Chen | May 2016 | S |
D758605 | Chen | Jun 2016 | S |
D758606 | Chen | Jun 2016 | S |
D759262 | Chen | Jun 2016 | S |
D759263 | Chen | Jun 2016 | S |
D759958 | Requa | Jun 2016 | S |
D762628 | Yoon et al. | Aug 2016 | S |
D762872 | Chen | Aug 2016 | S |
D767775 | Gilmer et al. | Sep 2016 | S |
9452287 | Rosenbluth et al. | Sep 2016 | B2 |
9474898 | Gozani et al. | Oct 2016 | B2 |
D774654 | Anderson | Dec 2016 | S |
D775361 | Vosch et al. | Dec 2016 | S |
D778453 | Knaus et al. | Feb 2017 | S |
D779677 | Chen | Feb 2017 | S |
9561397 | Zaki | Feb 2017 | B2 |
D784544 | Dudkiewicz et al. | Apr 2017 | S |
D784546 | Gordon | Apr 2017 | S |
D784946 | Jun et al. | Apr 2017 | S |
D788056 | Choi et al. | May 2017 | S |
9656070 | Gozani et al. | May 2017 | B2 |
D789546 | Matfus et al. | Jun 2017 | S |
D789547 | Matfus et al. | Jun 2017 | S |
D791333 | Wilson | Jul 2017 | S |
D792363 | Kim et al. | Jul 2017 | S |
9700724 | Liu et al. | Jul 2017 | B2 |
D794331 | Grote | Aug 2017 | S |
9731126 | Ferree et al. | Aug 2017 | B2 |
D798170 | Toth et al. | Sep 2017 | S |
D801542 | Anderson | Oct 2017 | S |
D802780 | Hsu | Nov 2017 | S |
9827420 | Ferree et al. | Nov 2017 | B2 |
D806669 | Kangasmaa et al. | Jan 2018 | S |
D810311 | Chen | Feb 2018 | S |
D810843 | Karvandi | Feb 2018 | S |
D810952 | Hsu | Feb 2018 | S |
D811729 | Bysshe | Mar 2018 | S |
D813405 | Ho | Mar 2018 | S |
D813407 | Chen | Mar 2018 | S |
D813408 | Chen | Mar 2018 | S |
D821592 | Pham et al. | Jun 2018 | S |
D828569 | Mercuro | Sep 2018 | S |
D829182 | Li | Sep 2018 | S |
10076662 | Tuan | Sep 2018 | B2 |
D830565 | Xu | Oct 2018 | S |
D831017 | Choe et al. | Oct 2018 | S |
D831221 | Smith | Oct 2018 | S |
D831335 | Crease | Oct 2018 | S |
D832230 | Lee et al. | Oct 2018 | S |
D834719 | Theriot et al. | Nov 2018 | S |
D836788 | Peng | Dec 2018 | S |
10154922 | Perez | Dec 2018 | B1 |
D837394 | Cryan et al. | Jan 2019 | S |
10279179 | Gozani et al. | May 2019 | B2 |
10335595 | Ferree et al. | Jul 2019 | B2 |
D857910 | Cryan et al. | Aug 2019 | S |
D861903 | Cryan et al. | Oct 2019 | S |
D861904 | Ho | Oct 2019 | S |
D862716 | Cryan et al. | Oct 2019 | S |
D865986 | Cryan et al. | Nov 2019 | S |
D879983 | Wang | Mar 2020 | S |
10940311 | Gozani | Mar 2021 | B2 |
11247040 | Ferree et al. | Feb 2022 | B2 |
20020010497 | Merfeld et al. | Jan 2002 | A1 |
20030023192 | Foxlin | Jan 2003 | A1 |
20030074037 | Moore et al. | Apr 2003 | A1 |
20030114892 | Nathan et al. | Jun 2003 | A1 |
20030208246 | Kotlik et al. | Nov 2003 | A1 |
20040049241 | Campos | Mar 2004 | A1 |
20040122483 | Nathan | Jun 2004 | A1 |
20040173220 | Harry | Sep 2004 | A1 |
20050059903 | Izumi | Mar 2005 | A1 |
20050080463 | Stahmann et al. | Apr 2005 | A1 |
20050097970 | Nurse | May 2005 | A1 |
20050131317 | Oddsson et al. | Jun 2005 | A1 |
20050234525 | Phillips | Oct 2005 | A1 |
20050283204 | Buhlmann et al. | Dec 2005 | A1 |
20060052788 | Thelen et al. | Mar 2006 | A1 |
20060064037 | Shalon | Mar 2006 | A1 |
20060085047 | Unsworth et al. | Apr 2006 | A1 |
20060085049 | Cory et al. | Apr 2006 | A1 |
20060089683 | Hagglof et al. | Apr 2006 | A1 |
20060095088 | De Ridder | May 2006 | A1 |
20060173507 | Mrva et al. | Aug 2006 | A1 |
20060190057 | Reese | Aug 2006 | A1 |
20060251334 | Oba et al. | Nov 2006 | A1 |
20070021786 | Parnis et al. | Jan 2007 | A1 |
20070060922 | Dreyfuss | Mar 2007 | A1 |
20070203435 | Novak | Aug 2007 | A1 |
20070203547 | Costello et al. | Aug 2007 | A1 |
20070276449 | Gunter et al. | Nov 2007 | A1 |
20080009772 | Tyler et al. | Jan 2008 | A1 |
20080077192 | Harry et al. | Mar 2008 | A1 |
20080146980 | Rousso et al. | Jun 2008 | A1 |
20080147143 | Popovic et al. | Jun 2008 | A1 |
20080147146 | Wahlgren et al. | Jun 2008 | A1 |
20080172102 | Shalev | Jul 2008 | A1 |
20080312709 | Volpe et al. | Dec 2008 | A1 |
20090030476 | Hargrove | Jan 2009 | A1 |
20090076364 | Libbus et al. | Mar 2009 | A1 |
20090082829 | Panken | Mar 2009 | A1 |
20090082831 | Paul | Mar 2009 | A1 |
20090112214 | Philippon et al. | Apr 2009 | A1 |
20090131993 | Rousso et al. | May 2009 | A1 |
20090203972 | Heneghan et al. | Aug 2009 | A1 |
20090240303 | Wahlstrand et al. | Sep 2009 | A1 |
20090264789 | Molnar et al. | Oct 2009 | A1 |
20090270947 | Stone et al. | Oct 2009 | A1 |
20090326604 | Tyler et al. | Dec 2009 | A1 |
20100004715 | Fahey | Jan 2010 | A1 |
20100010585 | Davis et al. | Jan 2010 | A1 |
20100042180 | Mueller et al. | Feb 2010 | A1 |
20100057149 | Fahey | Mar 2010 | A1 |
20100087903 | Van Herk et al. | Apr 2010 | A1 |
20100094103 | Kaplan et al. | Apr 2010 | A1 |
20100114257 | Torgerson | May 2010 | A1 |
20100131028 | Hsu et al. | May 2010 | A1 |
20100198124 | Bhugra | Aug 2010 | A1 |
20100217349 | Fahey | Aug 2010 | A1 |
20100241464 | Amigo et al. | Sep 2010 | A1 |
20100274304 | Wang et al. | Oct 2010 | A1 |
20110066209 | Bodlaender et al. | Mar 2011 | A1 |
20110106213 | Davis et al. | May 2011 | A1 |
20110166622 | Crosson et al. | Jul 2011 | A1 |
20110190594 | Heit et al. | Aug 2011 | A1 |
20110224665 | Crosby et al. | Sep 2011 | A1 |
20110245711 | Katra et al. | Oct 2011 | A1 |
20110257468 | Oser et al. | Oct 2011 | A1 |
20110264171 | Torgerson | Oct 2011 | A1 |
20110276107 | Simon et al. | Nov 2011 | A1 |
20110282164 | Yang et al. | Nov 2011 | A1 |
20120010680 | Wei et al. | Jan 2012 | A1 |
20120108998 | Molnar et al. | May 2012 | A1 |
20120123227 | Sun | May 2012 | A1 |
20120130449 | Carlyon et al. | May 2012 | A1 |
20120303077 | De Vincentiis | Nov 2012 | A1 |
20120319816 | Al-Ali | Dec 2012 | A1 |
20130079846 | Single | Mar 2013 | A1 |
20130096641 | Strother et al. | Apr 2013 | A1 |
20130116514 | Kroner et al. | May 2013 | A1 |
20130158627 | Gozani | Jun 2013 | A1 |
20130197341 | Grob et al. | Aug 2013 | A1 |
20130217998 | Mahfouz et al. | Aug 2013 | A1 |
20130317333 | Yang et al. | Nov 2013 | A1 |
20140005759 | Fahey et al. | Jan 2014 | A1 |
20140039450 | Green et al. | Feb 2014 | A1 |
20140057232 | Wetmore et al. | Feb 2014 | A1 |
20140081353 | Cook et al. | Mar 2014 | A1 |
20140088192 | Heller et al. | Mar 2014 | A1 |
20140107729 | Sumners et al. | Apr 2014 | A1 |
20140163444 | Ingvarsson et al. | Jun 2014 | A1 |
20140188194 | Schepis | Jul 2014 | A1 |
20140206976 | Thompson | Jul 2014 | A1 |
20140221797 | Bailey | Aug 2014 | A1 |
20140245784 | Proud et al. | Sep 2014 | A1 |
20140245791 | Proud et al. | Sep 2014 | A1 |
20140276236 | Swain | Sep 2014 | A1 |
20140276549 | Osorio | Sep 2014 | A1 |
20140296934 | Gozani et al. | Oct 2014 | A1 |
20140296935 | Ferree et al. | Oct 2014 | A1 |
20140309709 | Gozani et al. | Oct 2014 | A1 |
20140336725 | Nogueira | Nov 2014 | A1 |
20140336730 | Simon et al. | Nov 2014 | A1 |
20140343625 | O Laighin | Nov 2014 | A1 |
20140371547 | Gartenberg et al. | Dec 2014 | A1 |
20140371814 | Spizzirri et al. | Dec 2014 | A1 |
20140379045 | Rahimi et al. | Dec 2014 | A1 |
20150012068 | Bradley | Jan 2015 | A1 |
20150045853 | Alataris | Feb 2015 | A1 |
20150100107 | Kiani et al. | Apr 2015 | A1 |
20150157242 | Sabesan | Jun 2015 | A1 |
20150157868 | Franke et al. | Jun 2015 | A1 |
20150174402 | Thomas | Jun 2015 | A1 |
20150238094 | Lai et al. | Aug 2015 | A1 |
20150272511 | Najafi et al. | Oct 2015 | A1 |
20150306387 | Kong et al. | Oct 2015 | A1 |
20150321000 | Rosenbluth et al. | Nov 2015 | A1 |
20150328467 | Demers et al. | Nov 2015 | A1 |
20150335288 | Toth et al. | Nov 2015 | A1 |
20150335877 | Jeffery et al. | Nov 2015 | A1 |
20160007931 | Rubin et al. | Jan 2016 | A1 |
20160029891 | Lin | Feb 2016 | A1 |
20160113551 | Annegam et al. | Apr 2016 | A1 |
20160144174 | Ferree et al. | May 2016 | A1 |
20160151628 | Simon et al. | Jun 2016 | A1 |
20160166198 | Oddsson et al. | Jun 2016 | A1 |
20160189371 | Krishna Rao et al. | Jun 2016 | A1 |
20160213924 | Coleman et al. | Jul 2016 | A1 |
20160235981 | Southwell | Aug 2016 | A1 |
20160242646 | Obma | Aug 2016 | A1 |
20160243359 | Sharma | Aug 2016 | A1 |
20160250464 | Zschaeck et al. | Sep 2016 | A1 |
20160310730 | Martins | Oct 2016 | A1 |
20160367823 | Cowan et al. | Dec 2016 | A1 |
20170043160 | Goodall et al. | Feb 2017 | A1 |
20170056650 | Cohen et al. | Mar 2017 | A1 |
20170188864 | Drury | Jul 2017 | A1 |
20170188872 | Hughes et al. | Jul 2017 | A1 |
20170209693 | An | Jul 2017 | A1 |
20170224990 | Goldwasser et al. | Aug 2017 | A1 |
20170238812 | Atlas | Aug 2017 | A1 |
20170368345 | Kong et al. | Dec 2017 | A1 |
20180000685 | Maloney et al. | Jan 2018 | A1 |
20180028808 | Ferree et al. | Feb 2018 | A1 |
20180132757 | Kong et al. | May 2018 | A1 |
20180177996 | Gozani et al. | Jun 2018 | A1 |
20180345014 | Gozani et al. | Dec 2018 | A1 |
20190001135 | Yoo | Jan 2019 | A1 |
20190022372 | Dar | Jan 2019 | A1 |
20190022386 | Gozani | Jan 2019 | A1 |
20190134393 | Wong et al. | May 2019 | A1 |
20200179694 | Kong et al. | Jun 2020 | A1 |
20200219615 | Rabin et al. | Jul 2020 | A1 |
20210128904 | Terekhov | May 2021 | A1 |
20210260374 | Gozani | Aug 2021 | A1 |
Number | Date | Country |
---|---|---|
1665563 | Sep 2005 | CN |
1919139 | Feb 2007 | CN |
1926496 | Mar 2007 | CN |
101557788 | Oct 2009 | CN |
101626804 | Jan 2010 | CN |
102202131 | Sep 2011 | CN |
102355847 | Feb 2012 | CN |
102740919 | Oct 2012 | CN |
102010052710 | May 2012 | DE |
0 971 653 | Jan 2000 | EP |
1 985 277 | Feb 2015 | EP |
61-171943 | Oct 1986 | JP |
4-347140 | Dec 1992 | JP |
9-117453 | May 1997 | JP |
2000-167067 | Jun 2000 | JP |
2005-34402 | Feb 2005 | JP |
2005-81068 | Mar 2005 | JP |
2006-68300 | Mar 2006 | JP |
4185846 | Sep 2008 | JP |
WO 9742999 | Nov 1997 | WO |
WO 9964105 | Dec 1999 | WO |
WO 03051453 | Jun 2003 | WO |
WO 2004078132 | Sep 2004 | WO |
WO 2007061746 | May 2007 | WO |
WO 2008079757 | Jul 2008 | WO |
WO 2008088985 | Jul 2008 | WO |
WO 2009036313 | Mar 2009 | WO |
WO 2011075179 | Jun 2011 | WO |
WO 2011137193 | Nov 2011 | WO |
WO 2012116407 | Sep 2012 | WO |
WO 2013028960 | Feb 2013 | WO |
WO 2014172381 | Oct 2014 | WO |
WO 2015123373 | Aug 2015 | WO |
WO 2016201366 | Dec 2016 | WO |
WO 2018089655 | May 2018 | WO |
WO 2020033883 | Feb 2020 | WO |
Entry |
---|
Amazon, “Quell 2.0 Wearable Pain Relief Technology”, Sep. 15, 2018.http://www.amazon/com/Quell-Wearable-Pain-Relief-Technology/dp/B07DHW2MJJ/ref=cm_cr_arp_d_product_top? ie=UTF8. Shown on p. 1. (Year: 2018). |
Amazon, “Quell Wearable Pain Relief Technology Starter Kit”, Oct. 18, 2017. http://www.amazon.com/Quell-Wearable-ReliefTechnology-Starter/dp/B075YVCLZT/ref=cm_cr_arp_d_product_top?ie=UTF8. Shown on p. 1. (Year: 2017). |
Amft, O. et al., Sensing Muscle Activities with Body-Worn Sensors, Conference Paper, May 2006. |
Ancoli-Israel, S. et al., The Role of Actigraphy in the Study of Sleep and Circadian Rhythms, Sleep, 2003, 26(3), p. 342-392. |
Aurora, R. et al., The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults—An Update for 2012: Practice Parameters with an Evidence-Based Systematic Review and Meta-Analyses, Sleep, 2012, vol. 35, No. 8, p. 1039-1062. |
Barbarisi, Manlio et al., Pregabalin and Transcutaneous Electrical Nerve Stimulation for Postherpetic Neuralgia Treatment, The Clinical Journal of Pain, Sep. 2010;26(7):567-572. |
Bifulco, P. et al., A Stretchable, Conductive Rubber Sensor to Detect Muscle Contraction for Prosthetic Hand Control, The 6th IEEE International Conference on E-Health and Bioengineering—EHB 2017, Jun. 22-24, 2017, pp. 173-176. |
Bjordal JM et al., Transcutaneous electrical nerve stimulation (TENS) can reduce postoperative analgesic consumption. A meta-analysis with assessment of optimal treatment parameters for postoperative pain, Europe Journal of Pain, 2003, vol. 7(2): 181-188. |
Bloodworth DM et al., Comparison of stochastic vs. conventional transcutaneous electrical stimulation for pain modulation in patients with electromyographically documented radiculopathy, American Journal of Physical Medicine & Rehabilitation, 2004, vol. 83(8): 584-591. |
Bonnet, M. et al., Recording and Scoring Leg Movements, Sleep, 1993, vol. 16, No. 8, p. 748-759. |
Boyle, J. et al., Randomized, Placebo-Controlled Comparison of Amitriptyline, Duloxetine, and Pregabalin in Patients With Chronic Diabetic Peripheral Neuropathic Pain, Diabetes Care, 2012, vol. 35, p. 2451-2458. |
Chandran P et al., Development of opioid tolerance with repeated transcutaneous electrical nerve stimulation administration, Pain, 2003, vol. 102: 195-201. |
Chen CC et al., A comparison of transcutaneous electrical nerve stimulation (TENS) at 3 and 80 pulses per second on cold-pressor pain in healthy human participants, Clinical Physiology and Functioning Imaging, 2010, vol. 30(4): 260-268. |
Chen CC et al., An investigation into the effects of frequency-modulated transcutaneous electrical nerve stimulation (TENS) on experimentally-induced pressure pain in healthy human participants, The Journal of Pain, 2009, vol. 10(10): 1029-1037. |
Chen CC et al., Differential frequency effects of strong nonpainful transcutaneous electrical nerve stimulation on experimentally induced ischemic pain in healthy human participants, The Clinical Journal of Pain, 2011, vol. 27(5): 434-441. |
Chen CC et al., Does the pulse frequency of transcutaneous electrical nerve stimulation (TENS) influence hypoalgesia? A systematic review of studies using experimantal pain and healthy human participants, Physiotherapy, 2008, vol. 94: 11-20. |
Claydon LS et al., Dose-specific effects of transcutaneous electrical nerve stimulation on experimental pain, Clinical Journal of Pain, 2011, vol. 27(7): 635-647. |
Cole, R.J. et al., Automatic Sleep/Wake Identification From Wrist Activity, Sleep, 1992, 15(5), p. 461-469. |
Cruccu G. et al., EFNS guidelines on neurostimulation therapy for neuropathic pain, European Journal of Neurology, 2007, vol. 14: 952-970. |
Dailey DL et al., Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain, Fatigue, and Hyperalgesia while Restoring Central Inhibition in Primary Fibromyalgia, Pain, Nov. 2013, vol. 154, No. 11, pp. 2554-2562. |
Dailey, D. et al., Transcutaneous Electrical Nerve Stimulation Reduces Movement-Evoked Pain and Fatigue: A Randomized, Controlled Trial, Arthritis & Rheumatology, May 2020, vol. 72, No. 5, pp. 824-836. |
Davies HTO et al., Diminishing returns or appropriate treatment strategy?—an analysis of short-term outcomes after pain clinic treatment, Pain, 1997, vol. 70: 203-208. |
Desantana JM et al., Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain, Curr Rheumatol Rep. 2008, vol. 10(6): 492-499. |
Dubinsky RM et al., Assessment Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurology, Neurology, 2010, vol. 74: 173-176. |
Fary RE et al., Monophasic electrical stimulation produces high rates of adverse skin reactions in healthy subjects, Physiotherapy Theory and Practice, 2011, vol. 27(3): 246-251. |
Fishbain, David A. et al. Does Pain Mediate the Pain Interference with Sleep Problem in Chronic Pain? Findings from Studies for Management of Diabetic Peripheral Neuropathic Pain with Duloxetine, Journal of Pain Symptom Management, Dec. 2008; 36(6):639-647. |
Fishbain, David A. et al., Transcutaneous Electrical Nerve Stimulation (TENS) Treatment Outcome in Long-Term Users, The Clinical Journal of Pain, Sep. 1996; 12(3):201-214. |
Food and Drug Administration, Draft Guidance for Industry and Staff: Class II Special Controls Guidance Document: Transcutaneous Electrical Nerve Stimulator for Pain Relief, Apr. 5, 2010. |
Garrison DW et al., Decreased activity of spontaneous and noxiously evoked dorsal horn cells during transcutaneous electrical nerve stimulation (TENS), Pain, 1994, vol. 58: 309-315. |
Gilron, I. et al., Chronobiological Characteristics of Neuropathic Pain: Clinical Predictors of Diurnal Pain Rhythmicity, The Clinical Journal of Pain, 2013. |
Gozani SN et al., Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of Chronic Low Back and Lower Extremity Pain, Journal of Pain Research, 2016, vol. 9, pp. 469-479. |
Hausdorff, J.M. et al., Gait Variability and Fall Risk in Community-Living Older Adults: A 1-Year Prospective Study, Arch Phys Med Rehabil, Aug. 2001, vol. 82, pp. 1050-1056. |
Hori, T. et al., Skin Potential Activities and Their Regional Differences During Normal Sleep in Humans, The Japanese Journal of Physiology, 1970, vol. 20, p. 657-671. |
Jelinek HF et al., Electric pulse frequency and magnitude of perceived sensation during electrocutaneous forearm stimulation, Arch Phys Med Rehabil, 2010, vol. 91: 1372-1382. |
Jin DM et al., Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials, Diabetes Research and Clinical Practice, 2010, vol. 89: 10-15. |
Johnson MI et al., Analgesic effects of different frequencies of transcutaneous electrical nerve stimulation on cold-induced pain in normal subjects, Pain, 1989, vol. 39: 231-236. |
Johnson MI et al., Transcutaneous Electrical Nerve Stimulation (TENS) and TENS-like devices: do they provide pain relief?, Pain Reviews, 2001, vol. 8: 7-44. |
Johnson MI et al., Transcutaneous electrical nerve stimulation for the management of painful conditions: focus on neuropathic pain, Expert Review of Neurotherapeutics, 2011, vol. 11(5): 735-753. |
Johnson, M.I. et al., An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS). Implications for clinical use of TENS. Pain. Mar. 1991;44(3):221-229. |
Kaczmarek, Kurt A. et al.. Electrotactile and Vibrotactile Displays for Sensory Substitution Systems. IEEE Trans. Biomed. Eng. Jan. 1991;38 (1):1-16. |
Kantor G et al., The effects of selected stimulus waveforms on pulse and phase characteristics at sensory and motor thresholds, Physical Therapy, 1994, vol. 74(10): 951-962. |
Keller, Thierry et al., Electrodes for transcutaneous (surface) electrical stimulation. J. Automatic Control, University of Belgrade. 2008; 18(2):35-45. |
Koumans, A. J. R. et al., Electrodermal Levels and Fluctuations During Normal Sleep, Psychophysiology, 1968, 5(3), p. 300-306. |
Kovacevic-Ristanovic, R. et al., Nonpharmacologic Treatment of Periodic Leg Movements in Sleep, Arch. Phys. Med. Rehabil., 1991, vol. 72, p. 385-389. |
Kripke, D.F. et al., Wrist Actigraphic Scoring for Sleep Laboratory Patients: Algorithm Development, Journal of Sleep Research, 2010, 19(4), p. 612-619. |
Law PPW et al., Optimal stimulation frequency of transcutaneous electrical nerve stimulation on people with knee osteoarthritis, J Rehabil Med, 2004, vol. 36: 220-225. |
Leonard G et al., Deciphering the role of endogenous opioids in high-frequency TENS using low and high doses of naloxone, Pain, 2010, vol. 151: 215-219. |
Levy et al., A comparison of two methods for measuring thermal thresholds in diabetic neuropathy, Journal of Neurology, Neurosurgery, and Psychiatry, 1989, vol. 52: 1072-1077. |
Lopes, L. et al., Restless Legs Syndrome and Quality of Sleep in Type 2 Diabetes, Diabetes Care, 2005, vol. 28, No. 11, p. 2633-2636. |
Lykken, D.T., Properties of Electrodes Used in Electrodermal Measurement J. Comp. Physiol. Psychol. Oct. 1959; 52:629-634. |
Lykken, D.T., Square-Wave Analysis of Skin Impedance. Psychophysiology. Sep. 1970; 7(2):262-275. |
Macfarlane, T. et al., Whether the weather influences pain? Results from EpiFunD study in North West England, Rheumatology, 2010, vol. 49, pp. 1513-1520. |
Melzack R et al., Pain mechanisms: A New Theory, Science, 1965, vol. 150(3699): 971-979. |
Moran F et al., Hypoalgesia in response to transcutaneous electrical nerve stimulation (TENS) depends on stimulation intensity, The Journal of Pain, 2011, vol. 12(8): 929-935. |
Nightingale, S., The neuropathic pain market, Nature Reviews, 2012, vol. 11, p. 101-102. |
Okamoto-Mizuno. K. et al., Effects of thermal environment on sleep and circadian rhythm, Journal of Physiological Anthropology, 2012, vol. 31, No. 14, pp. 1-9. |
Oosterhof, Jan et al., Outcome of transcutaneous electrical nerve stimulation in chronic pain: short-term results of a double-blind, randomised, placebo-controlled trial. J. Headache Pain. Sep. 2006; 7 (4):196-205. |
Oosterhof, Jan et al., The long-term outcome of transcutaneous electrical nerve stimulation in the treatment for patients with chronic pain: a randomized, placebo-controlled trial. Pain Pract. Sep. 2012; 12(7):513-522. |
Ossipov MH et al., Central Modulation of Pain, The Journal of Clinical Investigation, Nov. 2010, vol. 120, No. 11, pp. 3779-3787. |
Pantaleao MA et al., Adjusting pulse amplitude during transcutaneous electrical nerve stimulation (TENS) application produces greater hypoalgesia, The Journal of Pain, 2011, vol. 12(5):581-590. |
Paquet, J. et al., Wake Detection Capacity of Actigraphy During Sleep, Sleep, 2007, 30(10), p. 1362-1369. |
Pieber K et al., Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review, Journal of Rehabilitation Medicine, 2010, vol. 42: 289-295. |
Raskin, J. et al., A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic Pain, Pain Medicine, 2005, 6(5), p. 346-356. |
Sadeh, A., The Role and Validity of Actigraphy in Sleep Medicine: An Update, Sleep Medicine Reviews, 2011, vol. 15, p. 259-267. |
Sadosky, A. et al., Burden of Illness Associated with Painful Diabetic Peripheral Neuropathy Among Adults Seeking Treatment in the US: Results from a Retrospective Chart Review and Cross-Sectional Survey, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, vol. 6, p. 79-92. |
Sano, A et al, Quantitative analysis of wrist electrodermal activity during sleep, International Journal of Psychophysiology, 2014, vol. 94, pp. 382-389. |
Scherder, E. J. A. et al., Transcutaneous Electrical Nerve Stimulation (TENS) Improves the Rest-Activity Rhythm in Midstage Alzheimer's Disease, Behavioral Brain Research, 1999, vol. 101, p. 105-107. |
Sheridan et al., Some Factors Influencing the Threshold of the Electrocutaneous Stimulus, Perceptual and Motor Skills, 1966, vol. 22, pp. 647-654. |
Susi et al., Motion Mode Recognition and Step Detection Algorithms for Mobile Phone Users, Sensors, Jan. 24, 2013, vol. 13, pp. 1539-1562. |
Taborri et al., A Novel HMM Distributed Classifier for the Detection of Gait Phases by Means of a Wearable Inertial Sensor Network, Sensors, Sep. 2014, vol. 14, pp. 16212-16234. |
Timmermans, E. et al., Self-perceived weather sensitivity and joint pain in older people with osteoarthritis in six European countries: results from the European Project on OSteoArthritis (EPOSA), BMC Musculoskeletal Disorders, 2014,, vol. 15, No. 66, pp. 1-11. |
Tryon, W. W., Issues of Validity in Actigraphic Sleep Assessment, Sleep, 2004, 27(1), p. 158-165. |
Tsai, Y. et al., Impact of Subjective Sleep Quality on Glycemic Control in Type 2 Diabetes Mellitus, Family Practice, 2012, vol. 29, p. 30-35. |
Van Boxtel, A., Skin resistance during square-wave electrical pulses of 1 to 10 mA. Med. Biol. Eng. Comput. Nov. 1977; 15(6):679-687. |
Van Someren, E. J. W. et al., Gravitational Artefact in Frequency Spectra of Movement Acceleration: Implications for Actigraphy in Young and Elderly Subjects, Journal of Neuroscience Methods, 1996, vol. 65, p. 55-62. |
Waeber, R. et al., Biosection Search with Noisy Responses, Siam J. Control Optim., 2013, vol. 51, No. 3, pp. 2261-2279. |
Webster, J. B. et al., An Activity-Based Sleep Monitor System for Ambulatory Use, Sleep, 1982, 5(4), p. 389-399. |
Zelman, D. C. et al., Sleep Impairment in Patients With Painful Diabetic Peripheral Neuropathy, The Clinical Journal of Pain, 2006, 22(8), p. 681-685. |
Zucconi, M. et al., The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG), Sleep Medicine, 2006, vol. 7, p. 175-183. |
Number | Date | Country | |
---|---|---|---|
20210260374 A1 | Aug 2021 | US |
Number | Date | Country | |
---|---|---|---|
62524195 | Jun 2017 | US | |
61858150 | Jul 2013 | US | |
61819159 | May 2013 | US | |
61811864 | Apr 2013 | US | |
61806481 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16010974 | Jun 2018 | US |
Child | 17196176 | US | |
Parent | 14269887 | May 2014 | US |
Child | 15824351 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15824351 | Nov 2017 | US |
Child | 16010974 | US | |
Parent | 14253628 | Apr 2014 | US |
Child | 14269887 | US | |
Parent | 14230648 | Mar 2014 | US |
Child | 14253628 | US |